Executive Certificate 米国２０２８年後発医薬品の安全評価とリスクアセスメント実践 Certification

"This course helped me develop a comprehensive understanding of safety evaluation and risk assessment practices for post-2028 generic drugs in the US, which has been invaluable in my role at a pharmaceutical company. I can now effectively assess and mitigate risks associated with these drugs."

"The course provided me with practical skills to evaluate the safety of post-2028 generic drugs in the US, including risk assessment and mitigation strategies, which has enhanced my ability to ensure patient safety in my current role."

"I gained a deeper understanding of the regulatory requirements for post-2028 generic drugs in the US and learned how to apply risk assessment tools to ensure compliance, which has been essential in my quality assurance role at a pharmaceutical manufacturing company."

"This course helped me understand the importance of safety evaluation and risk assessment in the development of post-2028 generic drugs in the US, and I can now apply this knowledge to design and conduct clinical trials that ensure patient safety and compliance with regulatory requirements."